You are here

  • Home
  • Archive
  • Volume 86, Issue 11
  • Long-term treatment of relapsing-remitting multiple sclerosis with interferon β: how strongly should we encourage patients to adhere to the ‘old’ therapies?

Article Text

Article menu
Download PDFPDF
Editorial commentary
Long-term treatment of relapsing-remitting multiple sclerosis with interferon β: how strongly should we encourage patients to adhere to the ‘old’ therapies?

https://doi.org/10.1136/jnnp-2015-310763

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests The author has received honoraria as a speaker and consultant from BIOGEN Inc, Genzyme, Merck Serono, Novartis and Teva in the last two years. He was involved as an investigator in clinical MS studies sponsored by BIOGEN, Merck Serono, Novartis, and Teva.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Multiple sclerosis
      Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
      Ludwig Kappos Jens Kuhle Juha Multanen Marcelo Kremenchutzky Elisabetta Verdun di Cantogno Peter Cornelisse Lorenz Lehr Florence Casset-Semanaz Delphine Issard Bernard M J Uitdehaag John King Michael Barnett Mark Freedman Joel Oger Magnhild Sandberg-Wollheim Cris Constantinescu Jacqueline Palace David Barnes Victoria Williams Benedicte Dubois Robert Medaer Christian Sindic Juha-Pekka Eralinna Heinz Wiendl Christoph Kleinschnitz
      Journal of Neurology, Neurosurgery & Psychiatry 2015; 86 1202-1207 Published Online First: 15 Sep 2015. doi: 10.1136/jnnp-2014-310024